1 clinical trials found.
-
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
You can participate in this study if you are diagnosed with ER+, HER2- Early Breast Cancer (Stages I-III) with an Increased Risk of Recurrence. And ...
